Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 65 |
| Active Pipeline (Recruiting Now) | 33 (18) |
| Completed vs Stopped Early | 6 / 6 (9.2%) |
| Median Closed Actual Enrollment | 35 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| University of Calgary | Calgary, Alberta | 24 |
| University of Alberta | Edmonton, Alberta | 4 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT07687056 | ACT-GLOBAL IA Thrombolysis(ACT-REACT-004)Domain Within the ACT-GLOBAL Adaptive Platform Trial-NCT06352632 | Phase III | RECRUITING |
| NCT06320431 | ACT-GLOBAL THROMBOLYSIS (ACT-WHEN-001) Domain Within the ACT-GLOBAL Adaptive Platform Trial-NCT06352632 | Phase III | RECRUITING |
Explore interactive annual charts and M&A subsidiary rollups in the University of Calgary Interactive Dossier, benchmark peers in Neurology, Psychiatry, and Pain, or review the Healthcare Price & Patent Cliff Crosswalk.